Ilex Oncology
Founded Year
1992Stage
Acq - P2P | AcquiredTotal Raised
$26.85MAbout Ilex Oncology
Ilex brings novel pharmaceutical treatments for cancer patients to market, with its first drug approval in 2001. Building on the successful launch of CamPath and the initiation of clinical trials of clofarabine, Ilex is advancing an innovative pipeline of additional drug candidates.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Ilex Oncology Frequently Asked Questions (FAQ)
When was Ilex Oncology founded?
Ilex Oncology was founded in 1992.
Where is Ilex Oncology's headquarters?
Ilex Oncology's headquarters is located at 4545 Horizon Hill Boulevard, San Antonio.
What is Ilex Oncology's latest funding round?
Ilex Oncology's latest funding round is Acq - P2P.
How much did Ilex Oncology raise?
Ilex Oncology raised a total of $26.85M.
Who are the investors of Ilex Oncology?
Investors of Ilex Oncology include Genzyme, Emory University, Janus Capital Group, Chartwell Investment Partners, Franklin Advisers and 25 more.
Who are Ilex Oncology's competitors?
Competitors of Ilex Oncology include Kiadis Pharma, Charleston Laboratories, Activate Immunotherapy, InClinica, Neuraltus Pharmaceuticals and 15 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Compare Ilex Oncology to Competitors
InClinica, formerly IndiPharm, is a global clinical CRO that specializes in leading companies through clinical trials, and works across all phases of clinical development, with a particular strength in assisting small to mid-sized companies.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.
Oncology Research Therapeutics, Inc. is dedicated to providing and discovering cancer diagnostics that improve the lives of patients suffering from a wide array of cancers. They also provide R&D services that improve drug development for the Biotech and Pharmaceutical industries.
Symphony Allegor is a drug company focused on treatment of acute agitation in patients with schizophrenia and bipolar disorder
PlantForm Corporation is a biotech company with a low-cost, proprietary manufacturing platform for a wide range of plant-made pharmaceuticals, including monoclonal antibodies, therapeutic proteins, and vaccines for the treatment of cancer, HIV/AIDS, Ebola virus, and other life-threatening illnesses.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
